lenvatinib 10mg is a type of targeted therapy which aim the specific cancer cells therefore reduces side effects caused by affected cells. lenvatinib 10mg is a multi-kinase inhibitor and antineoplastic agents lenvatinib 10mg interfering with a protein which promotes cell division by preventing the cancer cell growth.
Eisai Co. Ltd
INDICATION OF lenvatinib 10mg
lenvatinib 10mg is used in adult for the treatment of metastatic, progressive, radioactive Differentiated Thyroid cancer.
lenvatinib 10mg in combination with everolimus is used in patients for the treatment of advance Renal Cell Carcinoma following treatment before anti-angiogenic therapy
lenvatinib 10mg is also indicated for the first line treatment in patients suffering with unresectable hepatocellular carcinoma.
MECHANISM OF ACTION
Lenvatinib is a inhibitor of RTK (receptor tyrosine kinase) that interfere with the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
Lenvatinib also blocks other RTKs which have been suspected in pathogenic angiogenesis,growth of tumor, and cancer breakthrough in addition to their normal cellular activity, involves the fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet imitative growth factor receptor alpha (PDGFRα), KIT, and RET.
Duration of peak plasma concentration is 1 to 4 hours post dose. Effect with food is low to the extent Lenvatinibof absorption.
Lenvatinib binding to human plasma proteins is 98% to 99%.
lenvatinib 10mg is mainly metabolized in CYP3A. lenvatinib 10mg metabolic pathway is identified as enzymatic and non-enzymatic processes.
Excreted via 64% feces and 25% urine
DOSAGE AND ADMINISTRATION
The prescribed dose of Lenvatinib for the adult patients is 24mg and administer has two 10mg capsules and one 4mg capsule given orally, once daily taken with or without food. The Lenvatinib tablet should continue until disease progression or until unacceptable toxicity occurs. Take Lenvatinib tablet at the same time. Patients with severe renal or hepatic impairment the dose is 14mg administer once daily orally.
Lenvatinib is not expected to be dialyzable because of high plasma protein binding and if the dose receiving of lenvatinib 10mg 120mg orally then causes death due to multiorgan dysfunction occurred in the patients.
Common side effects
Tiredness, Peeling of skin on palms and sole of the feet, Constipation, Loss of appetite, Weight loss, Joint and muscle pain, Insomnia
Serious side effects
Shortness of breath, Chest pain, Pain in arm, back, neck or jaw, Seizures, Black, tarry or bloody stools, Heavy menstrual bleeding, Coughing up blood, Yellowing of the skin or eyes
Blood pressure may rises while treatment with lenvatinib 10mg . Your doctor will preferably check your blood pressure during your treatment.
Inform the doctor if you are allergic to lenvatinib 10mg , any other regimens, or any of the ingredients in lenvatinib 10mg capsules. other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may to change the doses of your drugs or guide carefully for adverse reaction.
OT interval Prolongation
Inform doctor if you have or had seizures, hypertension, a stroke, a heart attack, , especially those due to blood clots, a fistula, a tear in the wall of your GIT, QT interval prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death), low levels of Ca,K or Mg in your blood, bleeding problems, or cardiac, renal, or hepatic disease.
Take into the knowledge that lenvatinib 10mg may reduce the fertility in men and women. It not means that you or your partner cannot become pregnant. Inform doctor before if you are pregnant or plan to become pregnant. After becoming pregnant, you should use birth control while treatment with lenvatinib 10mg and for at least 2 weeks after your treatment, become pregnant duringLenvatinib therapy, call your doctor immediately. lenvatinib 10mg may harm the fetus. Inform the doctor if you are breastfeeding or plan to breastfeed. Avoid breastfeed during lenvatinib 10mg treatment.
DRUG – DRUG INTERACTION
- lenvatinib 10mg concomitant use with Carboplatin, paclitaxel has no specific pharmacokinetics impact
- Combination with CYP3A, Pglycoprotein (P-gp) inhibitors and inducers has no dose adjustment for lenvatinib 10mg